Technical Analysis for ADXS - Advaxis Inc

Grade Last Price % Change Price Change
C 0.1299 -2.91% -0.0039
ADXS closed down 2.91 percent on Friday, January 21, 2022, on 71 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down
Historical ADXS trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Hot IPO Pullback Bullish Swing Setup 0.00%
Doji - Bullish? Reversal 0.00%
Stochastic Reached Oversold Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
New 52 Week Closing Low Bearish -2.91%
Hot IPO Pullback Bullish Swing Setup -2.91%
Outside Day Range Expansion -2.91%
Older End-of-Day Signals for ADXS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Hot IPO Pullback Entry 4 days ago
Rose Above Previous Day's High 4 days ago
Down 10% 4 days ago
Outside Day 4 days ago
Down 5% 4 days ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Advaxis Inc Description

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Disease Prostate Cancer Immunotherapy Immunotherapies Non Small Cell Lung Cancer Treatment Of Non Small Cell Lung Cancer Prostvac Treatment Of Prostate Cancer Metastatic Prostate Cancer Seagen

Is ADXS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 0.2
52 Week Low 0.1112
Average Volume 2,232,346
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 0.1572
10-Day Moving Average 0.1519
Average True Range 0.0246
ADX 0.0
+DI 6.3718
-DI 14.3439
Chandelier Exit (Long, 3 ATRs) 0.1262
Chandelier Exit (Short, 3 ATRs) 0.1850
Upper Bollinger Bands 0.1846
Lower Bollinger Band 0.1298
Percent B (%b) 0.0
BandWidth 34.8601
MACD Line -0.0070
MACD Signal Line -0.0029
MACD Histogram -0.0041
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.1539
Resistance 3 (R3) 0.1538 0.1456 0.1499
Resistance 2 (R2) 0.1456 0.1395 0.1457 0.1486
Resistance 1 (R1) 0.1378 0.1357 0.1337 0.1379 0.1472
Pivot Point 0.1296 0.1296 0.1276 0.1297 0.1296
Support 1 (S1) 0.1218 0.1235 0.1177 0.1219 0.1126
Support 2 (S2) 0.1136 0.1197 0.1137 0.1112
Support 3 (S3) 0.1058 0.1136 0.1099
Support 4 (S4) 0.1059